Navigation Links
Fireflies help speed development of new drugs

The glow that fireflies are famous for, are due to a glow molecule present in their bodies. This glow molecule is now helping illuminate the effectiveness of new medicines and speed up the development of new drugs for various diseases like AIDS,// Alzheimer's, Cancer and others.

A study was carried out by researchers of the University of Michigan Health System who inserted the gene which is responsible for the firefly glow-producing molecule into mice with cancer. The researchers kept the molecule from producing the telltale glow until cells started to die in response to cancer treatment given to the mice. Researchers then used a highly sensitive camera to detect the glow in the mice as the cancer cells were destroyed by the drugs which was being tested.

Researchers concluded that the results of the study indicated that the glow molecule could aid in faster testing of new drugs for cancer, blood diseases, autoimmune disorders, heart attack damage and others, as these molecules could provide real time information about the effectiveness of new medications. Apart from the above use, these molecules could also be used to monitor the various cell processes.


'"/>




Page: 1

Related medicine news :

1. Emotional callers hamper speedy ambulance dispatch
2. New Drug, Pleconaril speeds recovery from common cold
3. FDA may speed review of new drugs
4. Magnetic Resonance Spectrometry for speedy diagnosis of Brain disorders
5. An unlikely contender for speedy surgery recovery: Chewing gum
6. Is There a Connection between Hearing loss and High-speed Dental Tools?
7. Cancer drugs in development nearly doubled since 1995
8. Role of zinc in development
9. Particulate matter affects lung development
10. Fossil teeth and human development
11. High development costs hinder entry of cancer super drugs into the market
Post Your Comments:
(Date:7/2/2009)...hreat, expert says , , THURSDAY, July 2 ...rtain species of wildlife, which need to be protec..., "Cancer is one of the leading health concerns f...human deaths. But we now understand that cancer ca... Denise McAloose, chief pathologist for the Wildli...
(Date:7/2/2009)...es need to be addressed in order to improve biomar...according to a commentary published online July 2 ... , The biomarker pipeline to develop and evaluat...on of promising biomarkers to detect cancers early...arkers for cancer screening. , In the commentar...
(Date:7/2/2009)...Call/ -- Nu Skin Enterprises, Inc. (NYSE: NUS ) ...r financial results prior to the market opening on...d chief executive officer, will host a conference ... day beginning at 11 a.m. (EDT). During the call,...s past results as well as upcoming business initia...
(Date:7/2/2009)... whereas seasonal flu doesn,t, researchers say, ,...Scientists have uncovered some intriguing clues ab...trointestinal distress and vomiting, symptoms not ...riments with ferrets, research teams in the United...1 flu virus replicated more extensively in the re...
Breaking Medicine News(10 mins):Health News:Cancer Endangers Some Wildlife Species 2Health News:Why Swine Flu Differs From Seasonal Flu 2Health News:Why Swine Flu Differs From Seasonal Flu 3
...t miss the wake of destruction caused by the India... and the Pakistan earthquake in late 2005. The tsu...00 lives with more than 100,000 still missing.// W...red as if the tourists were tsunami’s hot favorite...
...ries about autism are doing the rounds amongst the... that it is the right time to dissect these theori...p dispel some of the inaccurate assumptions surrou...iologist, a Psychiatrist and a physician will anal...
... have been raised against the use of Teflon. The E...at perfluorooctanoate a main ingredient used to ma... danger. // It was found that when the coated coo...s Fahrenheit then a person faces an unknown risk o...
...y of Medicine and Dentistry of New Jersey a state ...on S Corzine nominated Bruce C. Vladeck a national...its interim president. // Vladeck was in charge ...e Clinton administration. The school is in bad sha...
Other Medicine News:Health News:Autism: Symposium to Discuss Myths and Misconceptions 2
(Date:6/30/2009)..., AMSTERDAM, The Netherlands, June 30 /PRNewsw...on the Decision-Making Process With,Respect to In...nomic analysis presented today at this year,s,Eur... (ESHRE) congress showed,that, within the paramet...rtilisation (IVF) treatment MENOPUR (highly-purifi...
(Date:6/29/2009)..., ROCHESTER, Minn., June 29 /PRNewswire-USNewswire... the effectiveness of deep brain stimulation (DB...sive disorder (OCD) and Tourette,s syndrome are un...d, according to a review in the June 2009 issue of...ulation has long been seen as valuable for control...
(Date:6/29/2009)..., aTyr Pharma Targets for Novel Biotherapeutics Ba... SAN DIEGO, June 29 Pangu BioPharm... announced the filing of its third patent applicat...human tRNA synthetases. Although tRNA synthetases... synthesis machinery found in all organisms, human...
(Date:6/28/2009)..., RICHMOND, Calif., June 29 /PRNewswire-FirstCall/...day announced that a key research milestone has be...with Genentech, Inc., a wholly-owned member of the...h novel characteristics for pharmaceutical protein...inc finger DNA-binding protein nuclease (ZFN) tech...
Breaking Medicine Technology:New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 2New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 3New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 4Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases 2Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases 3Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3Niutang to Expand Sucralose Capacity 66 Percent by 2012 47221 1Niutang to Expand Sucralose Capacity 66 Percent by 2012 47221 2California to Become Only State Without Poison Control Services 47216 1California to Become Only State Without Poison Control Services 47216 2Community Businesses Impacted by Looming Cuts to Long Term Care Federal Funding 47213 1Community Businesses Impacted by Looming Cuts to Long Term Care Federal Funding 47213 2Community Businesses Impacted by Looming Cuts to Long Term Care Federal Funding 47213 3Community Businesses Impacted by Looming Cuts to Long Term Care Federal Funding 47213 4The vulnerable cancer cell 47209 1The vulnerable cancer cell 47209 2The vulnerable cancer cell 47209 3The vulnerable cancer cell 47209 4The vulnerable cancer cell 47209 5The vulnerable cancer cell 47209 6
...l 8, 2007 - Late-breaking Phase III,clinical trial...iety on Thrombosis and Haemostasis (ISTH) Congress...superior efficacy in the,prevention of venous thro...acement surgery in a head-to-head comparison with,... in the RECORD3,(REgulation of Coagulation in majo...
...SS WIRE)--July 9, 2007 - NexMed, Inc.,(NASDAQ: NEX...ts,based on the NexACT(R) drug delivery technology...leted patient enrollment for Phase,III clinical tr...ycosis (nail fungus). Pursuant to the terms of the... entitled to a milestone,payment early next year. ...
Other Medicine Technology:Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5NexMed Announces Completion of Patient Enrollment in Two Pivotal,Phase 3 Studies for Anti-Fungal Product 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator.
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag.
Malis CMC-III Generator provides both coagulation and cutting outputs.
Mc Kenzie-Downs Burr
Medicine Products: